Fecal microbiota transplantation alleviates mild‐moderate COVID‐19 associated diarrhoea and depression symptoms: A prospective study of a randomized, double‐blind clinical trial
Fäkale Mikrobiota-Transplantation lindert Durchfall und depressive Symptome bei milden bis moderaten COVID-19-Verläufen: prospektive Studie einer randomisierten, doppelblinden klinischen Studie
Journal of Medical Virology · 2024-08 · 96 (8)
DOI: 10.1002/jmv.29812 ↗Auf einen Blick
Bei 40 Patient:innen mit milden bis moderaten COVID-19-Verläufen war fäkale Mikrobiota-Transplantation mit weniger Durchfall und depressiven Symptomen verbunden als Placebo.
Fragestellung
Wirkt fäkale Mikrobiota-Transplantation bei COVID-19 mit milden bis moderaten Symptomen gegen Durchfall und depressive Symptome?
Methode
Randomisierte, doppelblinde, placebokontrollierte klinische Studie mit 40 COVID-19-Patient:innen.
Ergebnisse
Durchfall verbesserte sich unter fäkaler Mikrobiota-Transplantation (p = 0,026), ebenso Depression (p = 0,006). Die Zahl der Patient:innen mit Durchfall sank von 19 auf 0 an Tag 7; gegenüber Placebo war dies signifikant (p = 0,047).
Schlussfolgerung der Autor:innen
Die Autor:innen schließen, dass fäkale Mikrobiota-Transplantation eine neuartige therapeutische Strategie für COVID-19-Patient:innen mit Durchfall und depressiven Symptomen sein könnte.
Kernaussagen
- Weniger Durchfall unter fäkaler Mikrobiota-Transplantation
- Weniger depressive Symptome unter fäkaler Mikrobiota-Transplantation
- AST/ALT-Ratio sank von 0,966 auf 0,817
Deutsche Zusammenfassung: KI-gestützt aus dem Original-Abstract erstellt; alle Zahlen wurden automatisch mit dem Original abgeglichen. Maßgeblich ist der Original-Abstract.
Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Journal of Medical Virology, online erschienen am 26.07.2024. Verfasst von Xia Jiang und 15 weiteren Autor:innen. Beteiligte Einrichtung: Gastrointestinal Disease Diagnosis and Treatment Center, The First Hospital of Hebei Medical University, Shijiazhuang, Hebei, China. Hauptthemen laut MEDLINE: Fecal Microbiota Transplantation, COVID-19, Diarrhea, Depression. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 35 Literaturangaben. Gefördert von: Construction Funds of Hebei Key Laboratory of Colorectal Cancer Precision Diagnosis and Treatment from The First Hospital of Hebei Medical University; and othe…, National Natural Science Foundation of China, The Natural Science Foundation of Hebei.
Themen: Depression
Abstract (Originalsprache)
Currently, the emergence of the endemic Coronavirus disease (COVID‐19) situation still poses a serious threat to public health. However, it remains elusive about the role of fecal microbiota transplantation in treating COVID‐19. We performed a randomized, double‐blind, placebo‐controlled clinical trial enrolling a cohort of 40 COVID‐19 patients with mild‐moderate symptoms. Our results showed that fecal microbiota transplantation provided an amelioration in diarrhoea ( p = 0.026) of digestive system and depression ( p = 0.006) of neuropsychiatric‐related symptom in COVID‐19 patients, respectively. Meanwhile, we found that the number of patients with diarrhoea decreased from 19 to 0 on day 7 after fecal microbiota transplantation treatment, and it was statistically changed compared to the placebo group ( p = 0.047). Of note, the serum concentration of aspartate aminotransferase‐to‐alanine aminotransferase ratio (AST/ALT, fecal microbiota transplantation, pre vs. post: 0.966 vs. 0.817), a biomarker for predicting long COVID‐19, was significantly reduced by fecal microbiota transplantation. In all, our study supports that fecal microbiota transplantation could be a novel therapeutic strategy for COVID‐19 patients with diarrhoea and depressive symptoms, which is potentially valuable in ameliorating long COVID‐19 symptoms.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Gastrointestinal Disease Diagnosis and Treatment Center, The First Hospital of Hebei Medical University, Shijiazhuang, Hebei, China.
- Department of General Surgery, Hebei Key Laboratory of Colorectal Cancer Precision Diagnosis and Treatment, The First Hospital of Hebei Medical University, Shijiazhuang, Hebei, China.
- Physical Examination Center, The First Hospital of Hebei Medical University, Shijiazhuang, Hebei, China.
- Department of Clinical Laboratory, The First Hospital of Hebei Medical University, Shijiazhuang, Hebei, China.
ORCID-Profile: Chengyang Chen, Zengren Zhao
Förderung
- Construction Funds of Hebei Key Laboratory of Colorectal Cancer Precision Diagnosis and Treatment from The First Hospital of Hebei Medical University; and othe…
- National Natural Science Foundation of China
- The Natural Science Foundation of Hebei
- Hebei Provincial Department of Human Resources and Social Security
Zitieren
APA
Jiang, X., Gao, X., Ding, J., Pang, B., Pei, Y., Zhao, Z., Zhao, N., Wang, Z., Chen, C., Gao, D., Yan, F., Wang, F., Liu, C., Zhang, Z., Li, Z., & Zhao, Z. (2024). Fecal microbiota transplantation alleviates mild‐moderate COVID‐19 associated diarrhoea and depression symptoms: A prospective study of a randomized, double‐blind clinical trial. Journal of Medical Virology, 96(8). https://doi.org/10.1002/jmv.29812
Vancouver
Jiang X, Gao X, Ding J, Pang B, Pei Y, Zhao Z, et al. Fecal microbiota transplantation alleviates mild‐moderate COVID‐19 associated diarrhoea and depression symptoms: A prospective study of a randomized, double‐blind clinical trial. Journal of Medical Virology. 2024;96(8). doi:10.1002/jmv.29812
BibTeX
@article{Jiang2024,
author = {Jiang, Xia and Gao, Xian and Ding, Jiaqi and Pang, Bo and Pei, Yongbin and Zhao, Zifeng and Zhao, Ning and Wang, Zibin and Chen, Chengyang and Gao, Da and Yan, Fu and Wang, Feifan and Liu, Chengcheng and Zhang, Zheng and Li, Zhongxin and Zhao, Zengren},
title = {Fecal microbiota transplantation alleviates mild‐moderate COVID‐19 associated diarrhoea and depression symptoms: A prospective study of a randomized, double‐blind clinical trial},
journal = {Journal of Medical Virology},
year = {2024},
volume = {96},
number = {8},
doi = {10.1002/jmv.29812}
}
EUVIMED